Dr Timothy Wells
Chief Scientific Officer
Medicines for Malaria Venture
Dr Timothy Wells has been the Chief Scientific Officer of Medicines for Malaria Venture (MMV) since 2007, building and managing a portfolio of new medicines.
In collaboration with a wide network of partners, MMV has launched 9 products over this period, which are used to treat millions of children annually, and have contributed to saving the lives of 1.9 million children.
Prior to joining MMV, he had 20 years in the pharmaceutical biotech industry, initially with Glaxo’s Institute for Molecular Biology, and then as Head of Research for the Swiss biotech company Serono.
He received his PhD in Chemistry in 1987, on engineering enzyme transition states with Professor Sir Alan Fersht at Imperial College, London; and his ScD in Biology in 2009, from Cambridge University in the UK, for work on cytokine biology. He is a fellow of the UK’s Royal Society of Chemistry and Academy of Medical Sciences.